库马林-二甲基酸盐衍生物作为生物剂
Piotr Wiliński1, Aleksander Kurzątkowski1, Kinga Ostrowska1
1Department of Organic and Physical Chemistry, Faculty of Pharmacy, Medical University of Warsaw, Banacha 1, 02-097 Warsaw, Poland.
International journal of molecular sciences
|October 16, 2025
概括
库马林-二甲基酸盐混合物显示出显著的抗癌,抗微生物和神经保护作用. 本综述强调了它们的合成和多样化的生物活动,提供了新的治疗策略.
科学领域:
- 药用化学 医学化学
- 有机化学 有机化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 库马林衍生物具有广泛的生物活性,易于修改.
- 最初是杀虫剂的狄氏碳酸,显示出对抗癌症和感染的治疗潜力.
- 库马林-二甲基酸盐混合物结合了这两种支架的特性.
研究的目的:
- 审查近期库马林-二二甲基酸盐衍生物化学的进展.
- 专注于这些混合化合物的多样化的生物活动.
- 突出其在治疗癌症,微生物感染和神经退行性疾病方面的潜力.
主要方法:
- 库马林-二甲基酸盐合成和生物评估的文献综述.
- 结构与活动关系的分析.
- 关于细胞毒性,抗微生物,神经保护性和酶抑制作用的数据汇编.
主要成果:
- 库马林-二甲基酸盐对各种癌症细胞系表现出强烈的细胞毒性活性.
- 这些杂交物体表现出显著的抗微生物和抗真菌特性,解决了耐药性.
- 证据表明中枢神经系统的活动,包括乙胆酶和单胺氧化酶的抑制.
- 还报告了α-葡萄糖酶抑制作用和有前途的抗微生物活性.
结论:
- 库马林-二二甲基酸盐衍生物代表了一类有前途的化合物,具有多样化的治疗应用.
- 它们的多功能生物特征值得进一步研究以开发药物.
- 本次审查巩固了当前的知识,强调了它们对抗癌症,感染和神经系统疾病的潜力.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.1K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.7K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.7K
Therapeutic Drug Monitoring: Overview and Classification
306
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
306
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
1.5K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
1.5K
Cholinergic Antagonists: Pharmacokinetics
896
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
896
Targets for Drug Action: Overview
10.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.0K


